FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:88-90 July 5, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kimberlin, D. W. PubMed Citation

To the Editor: In their article about the varicella–zoster virus (VZV) vaccine for the prevention of herpes zoster, Kimberlin and Whitley (March 29 issue)¹ mention that the frequency and type of serious adverse events were similar for the vaccinees and placebo recipients. However, in the Adverse Event Monitoring Substudy, which involved a closely followed subgroup of 3345 recipients of the VZV vaccine (Zostavax, Merck) and 3271 placebo recipients, the rate of serious adverse events was higher among the vaccine recipients than among the placebo recipients (1.9% vs. 1.3%; relative risk, 1.53; 95% confidence interval, 1.04 to 2.25).² To assess further . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.